IN THE CLAIMS

1. (Cancelled)

2. (Currently Amended) ~~The~~ A pharmaceutical composition ~~according to claim 1 wherein said~~ comprising a LTB_4 antagonist ~~is a compound~~ of formula (I)



(I)

wherein

R represents a hydrogen atom or a group of formula $–CO_2$-R', in which R' represents a C_{1-6} alkyl, an optionally substituted phenyl or an optionally substituted benzyl group, wherein the optional substituents are selected from halogen atoms C_{1-6} alkyl, C_{1-6} alkoxy, cyano, nitro; C_{1-6} haloalkyl and C_{1-6} haloalkoxy groups, and A is a group selected from the ~~formulae~~ formula (A1) ~~and (A2)~~:



(A1)



(A2)

or a tautomer, a pharmaceutically acceptable salt or solvate thereof ~~(1).~~ and meloxicam of formula



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

3. (Currently Amended) ~~The~~ A pharmaceutical composition according to claim 2 consisting essentially of the compound of formula (IA)



(IA

~~(1) and a cyclooxygenase-2 inhibitor or combined cox1/coxII inhibitor selected from the group consisting of celecoxib, Dupont Dup 697, etodolac, etoricoxib, flosulide, meloxicam, nimesulide, parecoxib, rofecoxib, Taisho NS-398 and valdecoxib or a pharmaceutically acceptable salt or solvate thereof (2), and a pharmaceutically acceptable carrier or excipient.~~ and meloxicam of formula



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

4. (Cancelled)

5. (Currently Amended) ~~The composition~~ A pharmaceutical formulation according to ~~claim 1~~ claim 2 which is ~~in a form~~ suitable for oral, intravascular, intraperitoneal, subcutaneous, intramuscular or topical administration.

6. (Currently Amended) ~~The composition~~ A pharmaceutical formulation according to ~~claim 1~~ claim 2 wherein the weight ratio of ~~(1) to (2)~~ LTB_4 antagonist to meloxicam ranges from 50:1 to 1:300.

7. (Currently Amended) ~~The composition~~ A pharmaceutical formulation according to ~~claim 1~~ claim 2 wherein a single application dose contains 1 to 10,000 milligrams of the combined active ingredients ~~(1) and (2)~~.

8. (Currently Amended) ~~The composition~~ A pharmaceutical formulation according to ~~claim 1~~ claim 2 wherein the pharmaceutically acceptable carrier or excipient ~~comprises~~ is a carbohydrate.

9. (Withdrawn – Currently Amended) A method for the prevention or treatment of a disease or disorder selected from the group consisting of arthritis, including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus~~,~~ and juvenile arthritis, asthma, hay fever, atopic dermatitis, rhinitis, bronchitis, COPD, cystic fibrosis, psoriasis, sclerodermia, morbus bechterew, sarcoidosis, tumor metastasis, morbus crohn, colitis ulcerosa, IBD, multiple sclerosis, arteriosclerosis, arteritis, myocardial infarction, stroke, coronary heart disease ~~comprising the~~ which method comprises administration of ~~an~~ effective ~~amount~~ amounts of a composition ~~comprising a LTB_4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof (1) and a cyclooxygenase-2 or combined cox1/coxII inhibitor (2),~~ according to claim 2 to a patient in need thereof in a combined form, or separately or separately and sequentially.

10. (Withdrawn – Currently Amended) ~~The~~ A method according to claim 9 ~~wherein the composition is administered to a patient~~ for the prevention or treatment of rheumatoid arthritis, atopic dermatitis ~~or~~ and coronary heart disease.

11. (Withdrawn – Currently Amended) A method for the manufacture of a ~~medicamentation~~ medicament for the prevention or treatment of disease or disorder selected from the group consisting of arthritis, including rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, asthma, bronchitis, COPD and cystic fibrosis comprising mixing a LTB_4 antagonist ~~having a hydroxy and a benzamidine group, or a tautomer, a pharmaceutically acceptable salt or solvate thereof (1)~~ according to claim 2 and meloxicam ~~a cyclooxygenase-2 inhibitor or combined cox1/2 inhibitor (2)~~ in a combined form.

12. (Withdrawn – Currently Amended) The method according to claim 11 wherein the ~~medicamentation~~ medicament ~~is effective~~ for the prevention or treatment of rheumatoid arthritis, atopic dermatitis and coronary heart disease.

13. (Currently Amended) A pharmaceutical kit comprising at least two separate unit dosage forms (A) and (B) ~~in which~~:

(A) comprises a composition containing a LTB_4 antagonist ~~having a hydroxyl and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof (1)~~, of formula (I)



(I)

wherein

R represents a hydrogen atom or a group of formula $–CO_2$-R', in which R' represents a C_{1-6} alkyl, an optionally substituted phenyl or an optionally substituted benzyl group, wherein the optional substituents are selected from

halogen atoms C_{1-6} alkyl, C_{1-6} alkoxy, cyano, nitro; C_{1-6} haloalkyl and C_{1-6} haloalkoxy groups, and A is a group selected from the formula (A1):



(A1)

or a tautomer, a pharmaceutically acceptable salt or solvate thereof and optionally a pharmaceutically acceptable carrier; and

(B) comprises meloxicam ~~a composition containing a cyclooxygenase-2 inhibitor or combined cox1/2 inhibitor~~, and optionally a pharmaceutically acceptable carrier or excipient.

14. (New) A pharmaceutical formulation according to claim 3 which is suitable for oral, intravascular, intraperitoneal, subcutaneous, intramuscular or topical administration.

15. (New) A pharmaceutical formulation according to claim 3 wherein the weight ratio of LTB_4 antagonist to meloxicam ranges from 50:1 to 1:300.

16. (New) A pharmaceutical formulation according to claim 3 wherein a single application dose contains 1 to 10,000 milligrams of the combined active ingredients.

17. (New) A pharmaceutical formulation according to claim 3 wherein the pharmaceutically acceptable carrier or excipient is a carbohydrate.